However, the objective response rate (ORR) with cisplatin-based chemotherapy in NET G3 (Ki-67 < 55%) is much lower than in NEC and cisplatin/etoposide is not recommended and temozolomide-based chemotherapies or STZ-based chemotherapy in the case of pancreatic origin are mostly recommended (Pavel et al. 2020). Here, MKI67 is linked to neuroendocrine carcinoma.